James Marion

James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Applied Optoelectronics Inc. (AAOI) Surges in After-hours on Revised Revenue Projections

Applied Optoelectronics Inc. – Nasdaq: AAOI

Shares of Applied Optoelectronics Inc. surged over 20% in after-hours trading on news that future earnings will be above street estimates. AAOI revised revenue projections to between $84.5 and $84.8 million – well above previous projections between $75 and $79 million. Traded on the Nasdaq under ticker symbol AAOI, the shares ended the regular session at $22.72 however in the after-hours market the shares rose to $27.50.

Los Angeles, CA-based Applied Optoelectronics, Inc. designs, manufactures, and sells fiber-optic networking products primarily for internet data centers, cable television, and fiber-to-the-home networking end-markets.

From their press release:

“”We delivered a strong fourth quarter with top and bottom-line results expected to exceed our guidance,” said Dr. Thompson Lin, Applied Optoelectronics, Inc. founder, president and CEO. “Accelerated demand for our market-leading datacenter products and increased capacity fueled our results. Additionally, we continued to drive manufacturing efficiencies, which contributed to a record gross margin. We are excited by the good close to the year and look forward to sharing the additional details of our fourth quarter performance on our conference call in February.”

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/11/2017
Ticker Symbol SGNL
Last Price a/o 6:57 PM EST  $                    27.05
Average Volume 377,600
Market Cap $397.6 million
Sales $228.8 million
Shares Outstanding 17.5 million
Share Float 16.34 million
Shortable Yes
Optionable Yes
Inside Ownership 2.10%
Short Float 13.10%
Short Interest Ratio 5.67
Quarterly Return 3.09%
YTD Return -3.07%
Year Return 52.18%

Derma Sciences (Nasdaq: DSCI) Soars on Buyout

Derma Sciences Inc. – Nasdaq: DSCI

Derma Sciences Inc. shares shot up over 39% on news that the company has agreed to be bought out by Integra Life Sciences (IART). Derma Sciences Inc. shares, traded on the Nasdaq under ticker DSCI, settled at $6.95 – five cents below the buyout price of $7.00.

Derma Sciences is a Tissue Regeneration Company that claims to be at the forefront of research and innovation for the management of acute and chronic wounds, and burns. Stephen Wills, executive chairman at Derma stated “”Both Integra and Derma have a significant commitment to tissue regeneration, wound care and patient care. Derma’s portfolio of biologics and advanced wound care products are a natural extension of Integra’s business, and with Integra’s global presence, our products will reach a much larger and broader set of clinicians and patients.”

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

 

Uranium Resources, Inc. (Nasdaq: URRE) Up Big

Uranium Resources, Inc. – Nasdaq: URRE

Shares of Centennial, CO-based Uranium Resources Inc. are up over 45% on heavy volume. The explorer, developer, and producer of energy related metal trades on the Nasdaq under ticker URRE. URRE closed Tuesday at $2.25 and has reached $3.44 in early trading. Year-to-date, URRE has appreciated over 60%.

The company owns and operates the Temrezli ISR project in Central Turkey; and controls exploration properties under nine exploration and operating licenses covering approximately 32,000 acres. The company also holds interest in approximately 190,000 acres of mineral holdings in the prolific Grants Mineral Belt of the State of New Mexico; and 14,000 acres in the South Texas uranium province. In addition, it holds an agreement to acquire certain placer mining claims in the Sal Rica lithium brine project that covers an area of approximately 9,800 acres located in the Pilot Valley region of northwestern Utah.

Only one firm follows Uranium Resources, Inc. and their analyst gives shares of URRE a “Strong Buy” rating.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/11/2017
Ticker Symbol URRE
Last Price a/o 10:34 AM EST  $                      6.40
Average Volume 1.34 million
Market Cap $31.3 million
Sales
Shares Outstanding 13.9 million
Share Float 13.34 million
Shortable Yes
Optionable No
Inside Ownership 0.20%
Short Float 13.34%
Short Interest Ratio 0.71
Quarterly Return 63.04%
YTD Return 64.23%
Year Return -60.94%

Sarepta Therapeutics, Inc. (Nasdaq: SRPT) Posting Gains

Sarepta Therapeutics, Inc. – Nasdaq: SRPT

Shares of Sarepta Therapeutics, Inc. have been up almost 15% in early trading. SRPT is traded on the Nasdaq. On Monday SRPT closed at $31.26 and this morning shares have reached $37.40.

Cambridge, MA-based Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. Sarepta Therapeutics Inc. secured, in 2016, an FDA accelerated approval for their drug Exondys 51. In the fourth quarter, Sarepta recorded $5.4 million in sales of Exondys 51.

Sarepta CEO Ed Kaye stated “We want to make sure that everybody knows the physicians and their patients are interested in Exondys. This [the $5.4 million in sales] is the proxy for that. It’s really not a bad number for a first quarter…”

Reports of bearish investor sentiment stem from a publicized dispute within FDA about the approval decision and reports of insurance companies denying DMD patients access to the drug. CEO Kaye acknowledges the reimbursement process for Exondys 51 has been challenging. Some patients have been rejected by their insurance carriers.

Reported sales for Sarepta Therapeutics Inc. have been declining annually since 2011 when it reported $47 million, in 2015 reported sales were just $1.3 million. Of the fourteen firms that rate SRPT, eight rate it as a “Strong Buy”, two rate SRPT as a “Buy”, and four rate it as a “Hold”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

 

Ariad Pharmaceuticals (Nasdaq: ARIA) Agrees to $5.2 Billion Buy-out

Ariad Pharmaceuticals, Inc. – Nasdaq: ARIA

Takeda Pharmaceutical Company Inc. has agreed to purchase Cambridge, MA-based Ariad Pharmaceuticals for $24 per share. Ariad’s shares, traded on the Nasdaq under ticker ARIA, closed Friday at $13.74 and shot up to an intraday high of $23.81. The $5.2 Billion deal represents a 75% premium over the Friday closing price.

ARIAD Pharmaceuticals, Inc. is focused on discovering, developing and commercializing precision therapies for patients with rare cancers. ARIAD is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia, lung cancer and other rare cancers. According to its website, Takeda conducts activities according to the corporate mission to “strive towards better health for people worldwide through leading innovation in medicine.”

Alexander J. Denner, Ph.D., Chairman of the ARIAD Board of Directors, said: “This transaction is a great outcome for ARIAD shareholders and brings hope to improve the lives of many cancer patients. It has been a pleasure to work with our outstanding management team and, on behalf of the board of directors, I extend our deepest gratitude to everyone at ARIAD for their unrelenting dedication.”

Ariad Pharmaceuticals is covered by nine firms. Five gave ARIA a rating of “Strong Buy”, two rated ARIA a “Hold”, and two rated ARIA a “Sell”. Their consensus price target was $13. While ARIA has never reported a profit, it sales have done well. In 2011 Ariad Pharmaceuticals reported sales of $25.3 million but in 2015 Ariad reported sales of $118.8 million.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/9/2017
Ticker Symbol ARIA
Last Price a/o 11:32 AM EST  $                    23.75
Average Volume 6.5 million
Market Cap $2.6 Billion
Sales $186.2 million
Shares Outstanding 189.4 million
Share Float 187.7 million
Shortable Yes
Optionable Yes
Inside Ownership 0.20%
Short Float 17.26%
Short Interest Ratio 13.45
Quarterly Return 2.92%
YTD Return 10.45%
Year Return 161.22%

Today’s Nasdaq Small-cap Winners $AKAO $GBT $EXAS $FOLD $BCRX

Today’s top Nasdaq Small-cap Winners $AKAO $EXAS $GBT $FOLD $BCRX

AKAO – Achaogen, Inc. +14.46%

Intraday – http://elite.finviz.com/publish/010417/AKAOc0i3l1835.png

Daily – http://elite.finviz.com/publish/010417/AKAOccdl18400326.png

 

EXAS – Exact Sciences Corp. +11.48%

Intraday –  http://elite.finviz.com/publish/010417/EXASc0i3l1836.png

Daily –  http://elite.finviz.com/publish/010417/EXASccdl18411282.png

GBT – Global Blood Therapeutics, Inc. +10.84%

Intraday –  http://elite.finviz.com/publish/010417/GBTc0i3l1837.png

Daily – http://elite.finviz.com/publish/010417/GBTccdl18426442.png

FOLD – Amicus Therapeutics, Inc. +9.75%

Intraday –  http://elite.finviz.com/publish/010417/FOLDc0i3l1838.png

Daily –  http://elite.finviz.com/publish/010417/FOLDccdl18420773.png

BCRX – BioCryst Pharmaceuticals, Inc. +8.18%

Intraday –  http://elite.finviz.com/publish/010417/BCRXc0i3l1843.png

Daily –  http://elite.finviz.com/publish/010417/BCRXc0dl1844.png

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Interpace Diagnostics (Nasdaq: IDXG) Shares Soar on BC/BS Agreement

Interpace Diagnostics Corp. – Nasdaq: IDXG

Interpace Diagnostics Corp. (Nasdaq: IDXG), announced today that it has entered in to an agreement with the Blue Cross Blue Shield (BCBS) Association’s Center for Clinical Effectiveness “Evidence Street”. This program provides the company with the opportunity to support further coverage determinations among Blue Cross Blue Shield and other health plans. Blue Cross Blue Shield’s 36 independent plans and Companies account for approximately 106 million covered lives in the U.S.

IDXG is trading up over 160% on the news. Jack E. Stover, President and CEO of Interpace Diagnostics stated, “We are excited about our evolving relationship with Blue Cross and Blue Shield’sEvidence Street which, we believe, will help ensure that we continue to develop and provide the information and data necessary to support and secure broader based insurance coverage and reimbursement for all of our products.  This relationship is another important milestone in our reimbursement strategy and, when added to our recent AETNA insurance approval for ThyraMIR  and New York State approval to market ThyGenX, bodes well for our commercial prospects in 2017 and beyond.”

Interpace Diagnostics provides diagnostic tests and pathology services for evaluating rancer risk. The Company currently has three commercialized molecular tests; PancraGen for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay and ThyraMIR, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/3/17
Ticker Symbol IDXG
Last Price a/o 11:47 AM EST $11.31
Average Volume 47,000
Market Cap $11.1 million
Sales $12.5 million
Shares Outstanding 2.52 million
Share Float 1.33 million
Shortable Yes
Optionable No
Inside Ownership 1.00%
Short Float
Short Interest Ratio
Quarterly Return 2650.00%
YTD Return 836.17%
Year Return 836.17%

Ocera Therapeutics Inc. (Nasdaq: OCRX) Up Big in Pre-Market

Ocera Therapeutics Inc. – Nasdaq: OCRX

Shares of Ocera Therepeutics Inc are up over 25% in pre-market trading. Shares are traded on the Nasdaq under the ticker symbol OCRX. Ocera Therapeutics is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with serious diseases in areas of high unmet medical need.

Ocera’s lead drug candidate, OCR-002, is an ammonia scavenger which aims to remove ammonia from the blood. Elevated ammonia is believed to be one of the primary causes of hepatic encephalopathy (HE). OCR-002 is the subject of STOP-HE, a Company-sponsored Phase 2b trial, a Company-sponsored Phase 1 trial, and two externally-sponsored Phase 2a trials. OCR-002 has received Orphan Drug designation in both the U.S. and Europe and has been granted Fast Track status by the U.S. Food and Drug Administration.

Four firms follow Ocera Therapeutics. All four of their analysts rate OCRX a “Strong Buy” with a consensus price target of $10. Analyst confidence may be rewarded as OCRX has experienced increasing, though negative, EPS every year since 2011. However sales have been minimal and interested investors should view OCRX and all biotech companies with extreme caution and perform their own due diligence.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

12/28/2016
Ticker Symbol OCRX
Last Price a/o 8:13 AM EST  $               3.00
Average Volume 266,900
Market Cap $50.95 million
Sales $0.1 million
Shares Outstanding 23.2 million
Share Float 22.7 million
Shortable Yes
Optionable Yes
Inside Ownership 0.40%
Short Float 0.74%
Short Interest Ratio 0.63
Quarterly Return -15.38%
YTD Return -29.49%
Year Return -30.60%

 

Second Sight Medical Products, Inc. (Nasdaq: EYES) Up on UK Gov’t Acceptance

Second Sight Medical Products Inc.; Nasdaq: EYES

The UK publicly-funded NHS system will fund blind patients with Retinitis Pigmentosa (RP) to receive treatment with the Argus® II Retinal Prosthesis System (Argus II) “bionic eye”. This news has sent shares of Second Sight Products, Inc. to $2.48 highs before settling back to a 13% gain at a price of $2.19. Second Sight Products, Inc. trades on the Nasdaq under the ticker EYES.

Will McGuire, President and CEO of Second Sight, said, “This is a major milestone for Second Sight because we are the only company able to demonstrate a favorable long-term benefit-to-risk statement up to five years after implantation for some RP patients. NHS England is known to be under significant financial pressure and also extremely selective in adopting innovative technologies – which must demonstrate sufficient value for money. We expect that this decision will be observed throughout the world by other healthcare agencies.”

Second Sight Medical Products, Inc., located in Sylmar, California, was founded in 1998 by Mr. Alfred Mann, Dr. Sam Williams and Gunnar Bjorg with the goal of creating a retinal prosthesis to provide sight to subjects blinded from outer retinal degenerations, such as retinitis pigmentosa. Second Sight currently employs over 85 employees and has a European office in Lausanne, Switzerland.

H.C. Wainwright initiated coverage of Second Sight Medical Products in June of 2015 and assigned EYES a rating of “Buy” with a price target of $21. Sales have increased year-on-year since 2012 when reported sales were $1.4 million. In 2015 reported sales were $9 million. EYES EPS have not performed as well however – Second Sight Medical Products has never posted a positive EPS and last year lost $0.56 EPS.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

12/22/2016
Ticker Symbol EYES
Last Price a/o 1:10 PM EST  $               2.18
Average Volume 316,600
Market Cap $81.9 million
Sales $5.6 million
Shares Outstanding 42.23 million
Share Float 24.36 million
Shortable Yes
Optionable Yes
Inside Ownership 0.50%
Short Float 14.94%
Short Interest Ratio 11.5
Quarterly Return -42.09%
YTD Return -67.06%
Year Return -72.64%

 

Century Aluminum Company (Nasdaq: CENX) Rises Steadily in Daily Trading

Century Aluminum Company; Nasdaq: CENX

Shares of Century Aluminum Company closed at $8.48 yesterday, opened a few cents higher, and have been on a steady climb throughout the day. At the time of this writing (2:24 PM EST) CENX was trading around today’s high of $9.50.

Century Aluminum Company is a global producer of primary aluminum and operates aluminum reduction facilities in the United States and Iceland. Century Aluminum Company operates three U.S. aluminum smelters, in Hawesville, Kentucky (Hawesville), Robards, Kentucky (Sebree) and Mt. Holly, South Carolina (Mt. Holly), and one smelter in Grundartangi, Iceland (Grundartangi). The company is traded on the Nasdaq under the ticker CENX.

Four well known investments banks cover shares of CENX and all provide a price target ($7) below current trading levels. All also have a neutral rating of “Hold” on CENX. Further investigation into breaking news reports produced no information that might suggest a reason for the stock’s steady rise today.

Sales for Century Aluminum Company have risen from $1.36 Billion (2011) to $1.95 Billion in 2015. However investors should also note that last year CENX produced an EPS loss of $0.55. Also of note is the Century Aluminum’s CFO recently left the company.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Ticker Symbol CENX
Last Price a/o 2:41 EST  $               9.53
Average Volume 1.99 million
Market Cap $756 million
Sales $1.36 Billion
Shares Outstanding 89.1 million
Share Float 49.3 million
Shortable Yes
Optionable Yes
Inside Ownership 0.20%
Short Float 23.80%
Short Interest Ratio 5.88
Quarterly Return 40.33%
YTD Return 92.08%
Year Return 122.25%